Desperate for Cash, Benitec Pitches Share-Purchase Plan to Investors; Firm Needs $380K to Stay Afloat | GenomeWeb
Moribund RNAi therapeutics firm Benitec last week proposed to its investors a share-purchase plan designed to raise at least Aus$500,000 ($380,845), the minimum the company would need to remain solvent.
But even if it is able to secure the funds necessary to stay afloat, the company said that it has no plans to restart its internal research and development activities, nor does it intend to retry its hand at becoming a US-based firm.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.